会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 91. 发明申请
    • PIGMENT MANUFACTURING PROCESS
    • 颜料制造工艺
    • WO1994010249A1
    • 1994-05-11
    • PCT/GB1993002157
    • 1993-10-20
    • ZENECA LIMITEDPIKE, Leslie, ClarkWOOLLVEN, Peter
    • ZENECA LIMITED
    • C09B48/00
    • C07D471/04C07C67/343C07C249/02C09B48/00C07C69/757
    • A process of preparing a quinacridone of formula (VII), wherein X is methyl, chloro or fluoro, and n is 0, 1 or 2, which comprises : (a) treating a dialkylsuccinate of formula (II), wherein R is alkyl of 1 to 3 carbons atoms, with at least the stoichiometric amount of a solution of a sodium alkoxide NaOR in an alcohol ROH, in a reaction medium principally comprising one or more aliphatic polyethers of the formula R [O(CH2)m]nOR wherein R is C1-4-alkyl, m is 2 or 3, and n is 1, 2, 3 or 4, at a temperature of 70 DEG C to 120 DEG C, and maintaining the reaction mixture at a temperature of from 90 DEG C to 150 DEG C for a period sufficient to complete the formation of the dialkylsuccinylsuccinate (III), cooling the reaction mixture; (b) adding an aniline of formula (IV), wherein X is methyl, chloro or fluoro, and n is 0, 1 or 2, acidifying the reaction mixture, heating it to 60 DEG C to 100 DEG C to convert the dialkylsuccinylsuccinate (III) in the dihydro dianilinoterephthalic ester (V) wherein X and n are as defined for formula (IV), cooling the reaction mixture and neutralising it; (c) heating the reaction mixture under a vacuum to distil off water, alcohol ROH, and any unreacted aniline, placing the reaction mixture under an inert atmosphere, optionally adding more aliphatic polyether, and heating the reaction mixture to a temperature of 225-300 DEG C, whereby the dihydro dianilinoterephthalic ester (V) is converted to the dihydroquinacridone (VI); and (d) adding a mono-, di- or tri-ethanolamine or a 2-alkoxyethanol of formula F OCH2CH2OH wherein R is C1-4-alkyl, making the reaction mixture alkaline, oxidising the dihydroquinacridone (VI) to form the quinacridone (VII), and recovering the quinacridone from the reaction mixture.
    • 制备式(VII)的喹吖啶酮的方法,其中X是甲基,氯或氟,n是0,1或2,其包括:(a)处理式(II)的二烷基琥珀酸酯,其中R是 1至3个碳原子,至少化学计量量为醇ROH中的醇钠NaOR溶液,主要包含一种或多种式R 1 [O(CH 2)m]的脂族聚醚的反应介质中, nOR 1其中R 1为C 1-4 - 烷基,m为2或3,n为1,2,3或4,温度为70℃至120℃,并保持反应混合物 在90℃至150℃的温度下,足以完成二烷基琥珀酰基琥珀酸盐(III)的形成,冷却反应混合物; (b)加入式(Ⅳ)的苯胺,其中X是甲基,氯或氟,n是0,1或2,酸化反应混合物,将其加热到60℃至100℃,将二烷基琥珀酰基琥珀酸酯 III)在二氢二苯胺基对苯二甲酸酯(V)中,其中X和n如式(IV)所定义,冷却反应混合物并中和; (c)在真空下加热反应混合物以蒸馏出水,醇ROH和任何未反应的苯胺,将反应混合物置于惰性气氛下,任选加入更多的脂族聚醚,并将反应混合物加热至225-300℃ 将二氢二苯胺基对苯二甲酸酯(V)转化为二氢喹吖啶酮(VI); 和(d)加入式F 2 OCH 2 CH 2 OH的单 - ,二 - 或三 - 乙醇胺或2-烷氧基乙醇,其中R 2是C 1-4 - 烷基,使反应混合物碱性,氧化二氢喹吖啶酮 )以形成喹吖啶酮(VII),并从反应混合物中回收喹吖啶酮。
    • 94. 发明申请
    • INDOLIZINES AS HERBICIDES
    • 不溶于除草剂
    • WO1994005662A1
    • 1994-03-17
    • PCT/EP1993002132
    • 1993-08-12
    • ZENECA LIMITEDMITCHELL, GlynnSMITH, Stephen, ChristopherCLARKE, Eric, Daniel
    • ZENECA LIMITED
    • C07D471/04
    • C07D471/04A01N43/90C07D471/14
    • A herbicidal composition comprising a compound of formula (I) or a tautomer or a quaternised derivative thereof where Y is a group of formula -CR1=CR2-CO- and R1, R2, R3, R4 and R5 are independently selected from hydrogen; optionally substituted alkyl; optionally alkenyl; optionally substituted alkynyl; optionally substituted aryl; optionally substituted aromatic heterocyclic; halo; nitro; cyano; a group OR6 where R6 is hydrogen or a salt thereof, carboxy or an ester thereof, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or optionally substituted aryl; carboxy or a salt, ester or amide derivative thereof; S(O)nR7 where n is 0, 1 or 2 and R7 is optionally alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aryl; NR8R9 where R8 and R9 are independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aryl and R9 may additionally be acyl, or R8 and R9 together with the nitrogen atom to which they are attached form a heterocyclic ring; or R1 and R2 and/or any adjacent two of R3, R4 and R5 together with the carbon atoms to which they are attached form an optionally substituted fused saturated or unsaturated carbocyclic or heterocyclic ring; in combination with a carrier or diluent.
    • 一种除草组合物,其包含式(I)化合物或其互变异构体或其季铵化衍生物,其中Y为式-CR1 = CR2-CO-基团,R1,R2,R3,R4和R5独立地选自氢; 任选取代的烷基; 烯基; 任选取代的炔基; 任选取代的芳基; 任选取代的芳族杂环; 光环; 硝基; 氰基; 任选取代的烷基,任选取代的烯基,任选取代的炔基或任选取代的芳基;其中R 6为氢或其盐,羧基或其酯,任选取代的烷基,任选取代的烯基, 羧基或其盐,酯或酰胺衍生物; S(O)n R 7,其中n为0,1或2,R 7为任选烷基,任选取代的烯基,任选取代的炔基或任选取代的芳基; NR 8 R 9,其中R 8和R 9独立地选自氢,任选取代的烷基,任选取代的烯基,任选取代的炔基或任选取代的芳基,R 9可以另外是酰基,或者R 8和R 9与它们所连接的氮原子一起形成杂环 环; 或R 1和R 2和/或R 3,R 4和R 5中的任何相邻的两个与它们所连接的碳原子一起形成任选取代的稠合饱和或不饱和碳环或杂环; 与载体或稀释剂组合。
    • 95. 发明申请
    • QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS
    • 喹啉衍生物作为平均合成酶抑制剂
    • WO1994005660A1
    • 1994-03-17
    • PCT/GB1993001802
    • 1993-08-24
    • ZENECA LIMITEDBROWN, George, RobertMALLION, Keith, BlakeneyWHITTAMORE, Paul, Robert, OwenBRITTAIN, David, Robert
    • ZENECA LIMITED
    • C07D453/02
    • C07D453/02
    • Compounds of formula (I) and their pharmaceutically acceptable salts in which R is hydrogen or hydroxy; R is hydrogen; or R and R are joined together so that CR -CR is a double bond; X is selected from -CH2CH2-, -CH=CH-, -C=C-, -CH2O-, -CH2NH-, -NHCH2-, -CH2CO-, -COCH2-, -CH2S- and -SCH2-; Ar is a phenylene moiety; Ar is a heteroaryl moiety; and wherein one or both of Ar and Ar may optionally bear one or more substituents independently selected from halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, di-alkylamino, N-alkylcarbamoyl, di-N,N-alkylcarbamoyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, halogeno-alkyl, carboxyalkyl and alkanoylamino; provided that when R is hydroxy, X is not selected from -NHCH2- and -SCH2-; are inhibitors of squalene synthase and hence useful in treating medical conditions in which a lowering of cholesterol is beneficial, such as hypercholesterolemia and atherosclerosis. Processes for preparing these derivatives, pharmaceutical compositions containing them are also described together with their use in medicine.
    • 式(I)化合物及其药学上可接受的盐,其中R 1是氢或羟基; R 2是氢; 或R 1和R 2连接在一起,使得CR 1 -CR 2是双键; X选自-CH 2 CH 2 - , - CH = CH - , - C = C - , - CH 2 O - , - CH 2 NH - , - NHCH 2 - , - CH 2 CO-,-COCH 2 - , - CH 2 S-和-SCH 2 - Ar 1是亚苯基; Ar 2是杂芳基部分; 并且其中Ar 1和Ar 2中的一个或两个可任选地具有一个或多个独立地选自卤素,羟基,氨基,硝基,氰基,羧基,氨基甲酰基,烷基,烯基,炔基,烷氧基,烷基氨基,二 - 烷基氨基,N-烷基氨基甲酰基,二-N,N-烷基氨基甲酰基,烷氧基羰基,烷硫基,烷基亚磺酰基,烷基磺酰基,卤代 - 烷基,羧基烷基和烷酰基氨基; 条件是当R 1是羟基时,X不选自-NHCH 2 - 和-SCH 2 - ; 是角鲨烯合酶的抑制剂,因此可用于治疗胆固醇降低有益的医学病症,例如高胆固醇血症和动脉粥样硬化。 制备这些衍生物的方法,含有它们的药物组合物也与其在医药中的用途一起被描述。
    • 97. 发明申请
    • POWDER COATING COMPOSITION
    • 粉末涂料组合物
    • WO1994001500A1
    • 1994-01-20
    • PCT/GB1993001423
    • 1993-07-07
    • ZENECA LIMITEDSATGURUNATHAN, RajasinghamHINDE, David, CharlesPADGET, John, ChristopherYEATES, Stephen, George
    • ZENECA LIMITED
    • C09D05/03
    • C09D151/00C09D5/03
    • Powder coating composition which comprises a hybrid polymer system in granular form of a polymer A formable from monomer(s) by aqueous suspension polymerisation and a polymer B, different to A, which polymer system has been obtained using a process which comprises dissolving polymer B in monomeric material to be used in the formation of polymer A, polymerising the monomer(s) to form polymer A using an aqueous suspension polymerisation process, and removing the aqueous phase to form a hybrid of the polymers A and B in granular form, and wherein polymer A and polymer B bear functional groups for imparting curability to the hybrid polymer system, and wherein further the hybrid polymer system has a number average molecular weight within the range of from 1,500 to 15,000.
    • 粉末涂料组合物,其包含通过水悬浮聚合可从单体形成的聚合物A的颗粒形式的混合聚合物体系和与A不同的聚合物B,该聚合物体系已经使用包括将聚合物B溶解在 用于形成聚合物A的单体材料,使用水悬浮聚合方法聚合单体以形成聚合物A,并除去水相以形成颗粒形式的聚合物A和B的杂化物,其中 聚合物A和聚合物B具有赋予混合聚合物体系固化性的官能团,并且其中该混合聚合物体系的数均分子量在1,500至15,000范围内。
    • 99. 发明申请
    • QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHETASE INHIBITORS
    • 喹啉衍生物作为平均合成酶抑制剂
    • WO1993024486A1
    • 1993-12-09
    • PCT/GB1993001165
    • 1993-06-02
    • ZENECA LIMITEDMALLION, Keith, Blakeney
    • ZENECA LIMITED
    • C07D453/02
    • C07D453/02
    • Quinuclidine derivatives of formula (I), and their pharmaceutically acceptable salts, in which R is hydrogen or hydroxy; R is hydrogen; or R and R are joined together so that CR -CR is a double bond; Ar is a phenylene moiety; Ar is a 6-membered heteroaryl moiety containing one or two nitrogen atoms; and wherein one or both of Ar and Ar may optionally bear one or more substituents such as halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, di-alkylamino, N-alkylcarbamoyl, di-N,N-alkylcarbamoyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, halogenoalkyl, alkanoylamino, alkylenedioxy, alkanoyl and oxime derivatives thereof and O-alkyl ethers of said oxime derivatives; inhibit squalene synthetase and are therefore useful in treating diseases and medical conditions where inhibition of squalene synthetase is desirable, for exemple in treating hypercholesterolemia and atherosclerosis. Processes for the preparation of these derivatives and pharmaceutical compositions containing them are also referred to as well as their use in medicine.
    • 式(I)的奎宁环衍生物及其药学上可接受的盐,其中R 1是氢或羟基; R 2是氢; 或R 1和R 2连接在一起,使得CR 1 -CR 2是双键; Ar 1是亚苯基; Ar 2是含有一个或两个氮原子的6元杂芳基部分; Ar 1和Ar 2中的一个或两个可以任选地具有一个或多个取代基,例如卤代,羟基,氨基,硝基,氰基,羧基,氨基甲酰基,烷基,烯基,炔基,烷氧基,烷基氨基, 烷基氨基,N-烷基氨基甲酰基,二-N,N-烷基氨基甲酰基,烷氧基羰基,烷硫基,烷基亚磺酰基,烷基磺酰基,卤代烷基,烷酰基氨基,亚烷基二氧基,烷酰基和肟衍生物和所述肟衍生物的O-烷基醚; 抑制角鲨烯合成酶,因此可用于治疗需要抑制角鲨烯合成酶的疾病和医学病症,例如治疗高胆固醇血症和动脉粥样硬化。 制备这些衍生物和含有它们的药物组合物的方法也被称为它们在医学中的用途。